, Organisation Mondiale de la Santé. Les 10 principales causes de mortalité

D. Sur,

H. Autorité-de-santé, Traiter l'hypercholestérolémie seule n'est pas suffisant dans la prise en charge du risque cardiovasculaire

, Données annuelles sur les médicaments remboursés par l'Assurance Maladie. Medic'AM 2017

A. Maladie, Usage des Statines

, Rapport sur les conditions de retrait du marché des spécialités contenant de la cérivastatine (Staltor® & Cholstat®) le 08 août 2001 et obligations de pharmacovigilance

, bis : Dyslipidémies. Universités médicales francophines, vol.129, p.129

C. Invs and U. Paris, Étude Nationale Nutrition Santé ENNS, 2006.

D. Sur,

F. Santé-publique, Maladies cardio-neuro-vasculaires

D. Sur,

A. Maladie, Les maladies cardiovasculaires

, Organisation Mondiale de la Santé

P. Bhatnagar, K. Wickramasinghe, E. Wilkins, and N. Townsend, Trends in the epidemiology of cardiovascular disease in the UK. Heart, vol.102, pp.1945-52, 2016.

, Public Health Agency of Canada. Chronic disease and injury indicator framework

D. Sur,

J. Ferrières and . Monica, Multinational MONItoring of trends and determinants in Cardiovascular disease -Registre des cardiopathies ischémiques de la Haute, 2011.

D. Sur,

P. Ducimetière, La fréquence des maladies cardio-vasculaires en France et en Europe. adsp, pp.20-22, 2004.

A. Maladie and . France,

D. Sur,

M. Farnier, Histoire des statines. Médecine Mal Métaboliques, vol.7, pp.407-419, 2013.

, Analyse des ventes de médicaments aux officines et aux hôpitaux en France 11 ème édition

, Medic'AM 2017 tous régimes. Données mensuelles et annuelles sur les médicaments remboursés par l'Assurance Maladie

D. Sur,

H. Autorité-de-santé, Traiter l'hypercholestérolémie seule n'est pas suffisant dans la prise en charge du risque cardiovasculaire

M. B. Mortensen and B. G. Nordestgaard, Comparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population, Ann Intern Med, vol.168, issue.2, pp.85-92, 2018.

, Organisation Mondiale de la Santé

D. Sur,

H. Autorité-de-santé, Définition de l'EDC selon le DSM-5

D. Sur,

E. Corruble, Les troubles de l'humeur selon le DSM-5 : quelles conséquences prévisibles? La Lettre du Psychiatre, 2014.

H. Autorité-de-santé, Dépression de l'adulte -Repérage et prise en charge initiale

D. Sur,

H. Autorité-de-santé, Episode dépressif caractérisé de l'adulte : prise en charge en soins de premier recours. Recommandations pour la pratique clinique

D. Sur,

H. Autorité-de-santé, Troubles dépressifs récurrents ou persistants de l'adulte

. Vidal-reco, Prise en charge de la dépression

C. D. Mathers and D. Loncar, Projections of global mortality and burden of disease from 2002 to 2030, PLoS Med, vol.3, issue.11, p.442, 2006.

F. Beck and F. La-dépression-en, ) : prévalence, recours au soin et sentiment d'information de la population. La santé de l'homme, pp.43-48, 2005.

A. Maladie, Données relatives aux patients nouvellement admis dans le dispositif des ALD une année donnée

D. Sur,

H. Autorité-de-santé, Dépression de l'adulte -Repérage et prise en charge initiale

H. Autorité-de-santé, Evaluation et prise en charge des personnes âgées faisant des chutes répétées

D. Sur, Aged -MeSH -NCBI

D. Sur, World Health Organization. Health situation and trend assessment. Elderly population

D. Sur, Institut national de la statistique et des études économiques

G. Berrut and L. De-decker, Comprehensive assessment of comorbidity in the elderly. Geriatr Psychol Neuropsychiatr Vieil, vol.13, pp.7-12, 2015.

M. Harboun, Épidémiologie des comorbidités chez les personnes âgées. NPG NeurolPsychiatr -Gériatrie, vol.7, pp.11-14, 2007.

, Bon usage des médicaments : antidépresseurs dans le traitement des troubles dépressifs et des troubles anxieux de l'adulte

F. Beck, R. Guignard, and F. La-dépression-en, ) : prévalence, recours au soin et sentiment d'information de la population. La santé de l'homme, pp.43-48, 2005.

. Legifrance, Article R1121-1 du Code de la Santé Publique

D. Sur,

, Differences between clinical trials and postmarketing use -Martin -2004, 2018.

, Agence Nationale de Sécurité des Médicaments et des produits de santé. DUTASTERIDE BIOGARAN 0.5 mg, capsule molle -Résumé des caractéristiques du produit

D. Sur,

H. Autorité-de-santé, Commission de la Transparence

R. W. Harrison and C. H. Ashton, Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers, Br J Clin Pharmacol, vol.37, issue.3, pp.231-237, 1994.

K. M. Davison and B. J. Kaplan, Lipophilic statin use and suicidal ideation in a sample of adults with mood disorders, Crisis, vol.35, issue.4, pp.278-82, 2014.

S. Kim, H. Kang, K. Bae, I. Shin, Y. J. Hong et al., Interactions between pro-inflammatory cytokines and statins on depression in patients with acute coronary syndrome, Prog Neuropsychopharmacol Biol Psychiatry, vol.80, pp.250-254, 2018.

O. Köhler-forsberg, C. Gasse, M. Berk, and S. D. Østergaard, Do Statins Have Antidepressant Effects? CNS Drugs, vol.31, pp.335-378, 2017.

B. M. Song, J. Lee, W. Choi, Y. Youm, S. H. Chu et al., Association between C reactive protein level and depressive symptoms in an elderly Korean population: Korean Social Life, Health and Aging Project, BMJ Open, vol.5, issue.2, p.6429, 2015.

M. Lechleitner, F. Hoppichler, G. Konwalinka, J. Patsch, and H. Braunsteiner, Depressive symptoms in hypercholesterolaemic patients treated with pravastatin. The Lancet, vol.340, p.910, 1992.

N. Duits and F. M. Bos, Depressive symptoms and cholesterol-lowering drugs. The Lancet, vol.341, p.114, 1993.

J. Kang, L. Kao, H. Lin, M. Tsai, and C. , Statin use increases the risk of depressive disorder in stroke patients: A population-based study, J Neurol Sci, vol.348, issue.1-2, pp.89-93, 2015.

J. Kim, R. Stewart, H. Kang, K. Bae, S. Kim et al., A prospective study of statin use and poststroke depression, J Clin Psychopharmacol, vol.34, issue.1, pp.72-81, 2014.

A. K. Parsaik, B. Singh, M. H. Murad, K. Singh, S. S. Mascarenhas et al., Statins use and risk of depression: a systematic review and meta-analysis, J Affect Disord, vol.160, pp.62-69, 2014.

M. Haghighi, S. Khodakarami, L. Jahangard, M. Ahmadpanah, H. Bajoghli et al., In a randomized, double-blind clinical trial, adjuvant atorvastatin improved symptoms of depression and blood lipid values in patients suffering from severe major depressive disorder, J Psychiatr Res, vol.58, pp.109-123, 2014.

S. W. Kim, K. Y. Bae, J. M. Kim, I. S. Shin, Y. J. Hong et al., The use of statins for the treatment of depression in patients with acute coronary syndrome. Transl Psychiatry, vol.5, p.620, 2015.

E. Salagre, B. S. Fernandes, S. Dodd, D. J. Brownstein, and M. Berk, Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials, J Affect Disord, vol.200, pp.235-277, 2016.

S. M. Lilly, E. M. Mortensen, C. R. Frei, M. J. Pugh, and I. A. Mansi, Comparison of the Risk of Psychological and Cognitive Disorders Between Persistent and Nonpersistent Statin Users, Am J Cardiol, vol.114, issue.7, pp.1035-1044, 2014.

S. Aijänseppä, P. Kivinen, E. Helkala, S. Kivelä, J. Tuomilehto et al., Serum cholesterol and depressive symptoms in elderly Finnish men, Int J Geriatr Psychiatry, vol.17, issue.7, pp.629-663, 2002.

A. While and L. Keen, The effects of statins on mood: a review of the literature, Eur J Cardiovasc Nurs, vol.11, issue.1, pp.85-96, 2012.

J. Wardle, J. Armitage, R. Collins, K. Wallendszus, A. Keech et al., Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group, BMJ, vol.13, issue.7049, pp.75-83, 1996.

M. B. Olson, S. F. Kelsey, K. A. Matthews, B. Merz, C. N. Eteiba et al., Lipid-lowering medication use and aggression scores in women: a report from the NHLBIsponsored WISE study, J Womens Health, vol.17, issue.2, pp.187-94, 2002.

R. A. Stewart, K. J. Sharples, F. M. North, D. B. Menkes, J. Baker et al., Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators, Arch Intern Med, vol.160, issue.20, pp.3144-52, 2000.

M. F. Muldoon, S. D. Barger, C. M. Ryan, J. D. Flory, J. P. Lehoczky et al., Effects of lovastatin on cognitive function and psychological well-being, Am J Med, vol.108, issue.7, pp.538-584, 2000.

J. V. Agostini, M. E. Tinetti, L. Han, G. Mcavay, J. M. Foody et al., Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults, J Am Geriatr Soc, vol.55, issue.3, pp.420-425, 2007.

K. Morales, M. Wittink, C. Datto, S. Difilippo, M. Cary et al., Simvastatin causes changes in affective processes in elderly volunteers, J Am Geriatr Soc, vol.54, issue.1, pp.70-76, 2006.

M. T. Hyyppä, E. Kronholm, A. Virtanen, A. Leino, and A. Jula, Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial, Psychoneuroendocrinology, vol.28, issue.2, pp.181-94, 2003.

A. Nationale-de-médecine and M. Komajda, Efficacité et effets indésirables des statines : évidences et polémiques

S. Ministère-des, L. De, and . Santé, Portail de signalement des évènements sanitaires indésirables

. Uppsala-monitoring and . Center, What is Vigibase?

J. Montastruc, A. Sommet, H. Bagheri, and M. Lapeyre-mestre, Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database, Br J Clin Pharmacol, vol.72, issue.6, pp.905-913, 2011.

P. Waller, E. Van-puijenbroek, A. Egberts, and S. Evans, The reporting odds ratio versus the proportional reporting ratio: "deuce, Pharmacoepidemiol Drug Saf, vol.13, issue.8, pp.527-528, 2004.

S. J. Evans, P. C. Waller, and S. Davis, Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports, Pharmacoepidemiol Drug Saf, vol.10, issue.6, pp.483-489, 2001.

M. Paludetto, P. Olivier-abbal, and J. Montastruc, Is spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France? Pharmacoepidemiol Drug Saf, vol.21, pp.1289-94, 2012.

, Medical Dictionary for Regulatory Activities

J. Faillie, Case-non case studies: Principles, methods, bias and interpretation, Therapie, vol.73, issue.3, pp.247-55, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01741153

M. Arnaud, F. Salvo, I. Ahmed, P. Robinson, N. Moore et al., A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases, Drug Saf, vol.39, issue.3, pp.251-60, 2016.

F. Salvo, F. Leborgne, F. Thiessard, N. Moore, B. Bégaud et al., A potential eventcompetition bias in safety signal detection: results from a spontaneous reporting research database in France, Drug Saf, vol.36, issue.7, pp.565-72, 2013.

C. Otte, S. Zhao, and M. A. Whooley, Statin use and risk of depression in patients with coronary heart disease: longitudinal data from the Heart and Soul Study, J Clin Psychiatry, vol.73, issue.5, pp.610-615, 2012.

, Agence Nationale de Sécurité du Médicament et des produits de santé, CRESTOR 20 mg

H. Autorité-de-santé, Améliorer la prescription des psychotropes chez les personnes âgées, Bilan d'étape, 2008.

B. Bégaud, K. Martin, F. Haramburu, and N. Moore, Rates of spontaneous reporting of adverse drug reactions in France, JAMA, vol.288, issue.13, p.1588, 2002.

M. Liu, A. Alafris, A. J. Longo, and H. Cohen, Irreversible atorvastatin-associated hearing loss, Pharmacotherapy, vol.32, issue.2, pp.27-34, 2012.

H. Géniaux, D. Assaf, G. Miremont-salamé, B. Raspaud, A. Gouverneur et al., Performance of the standardised MedDRA® queries for case retrieval in the French spontaneous reporting database, Drug Saf, vol.37, issue.7, pp.537-579, 2014.

B. Bégaud and . Armepharmacovigilance, Dictionnaire de pharmaco-épidémiologie

D. Sur,

B. Bégaud, J. C. Evreux, J. Jouglard, and G. Lagier, Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France, Therapie, vol.40, issue.2, pp.111-119, 1985.

, Arrêté du 28 avril 2005 relatif aux bonnes pratiques de pharmacovigilance

D. Sur,

Y. Arimone, I. Bidault, J. Dutertre, M. Gérardin, C. Guy et al., Réactualisation de la méthode française d'imputabilité des effets indésirables des médicaments, Thérapie, vol.66, issue.6, pp.517-542, 2011.